These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 14658963

  • 1. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study.
    Gothelf D, Gruber R, Presburger G, Dotan I, Brand-Gothelf A, Burg M, Inbar D, Steinberg T, Frisch A, Apter A, Weizman A.
    J Clin Psychiatry; 2003 Oct; 64(10):1163-9. PubMed ID: 14658963
    [Abstract] [Full Text] [Related]

  • 2. Genetic, developmental, and physical factors associated with attention deficit hyperactivity disorder in patients with velocardiofacial syndrome.
    Gothelf D, Presburger G, Levy D, Nahmani A, Burg M, Berant M, Blieden LC, Finkelstein Y, Frisch A, Apter A, Weizman A.
    Am J Med Genet B Neuropsychiatr Genet; 2004 Apr 01; 126B(1):116-21. PubMed ID: 15048660
    [Abstract] [Full Text] [Related]

  • 3. Behavior and corpus callosum morphology relationships in velocardiofacial syndrome (22q11.2 deletion syndrome).
    Antshel KM, Conchelos J, Lanzetta G, Fremont W, Kates WR.
    Psychiatry Res; 2005 Apr 30; 138(3):235-45. PubMed ID: 15854791
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH, Rohde LA.
    Arch Gen Psychiatry; 2007 Feb 30; 64(2):218-24. PubMed ID: 17283289
    [Abstract] [Full Text] [Related]

  • 6. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome.
    Green T, Weinberger R, Diamond A, Berant M, Hirschfeld L, Frisch A, Zarchi O, Weizman A, Gothelf D.
    J Child Adolesc Psychopharmacol; 2011 Dec 30; 21(6):589-95. PubMed ID: 22149470
    [Abstract] [Full Text] [Related]

  • 7. Manic symptoms and behavioral dysregulation in youth with velocardiofacial syndrome (22q11.2 deletion syndrome).
    Aneja A, Fremont WP, Antshel KM, Faraone SV, AbdulSabur N, Higgins AM, Shprintzen R, Kates WR.
    J Child Adolesc Psychopharmacol; 2007 Feb 30; 17(1):105-14. PubMed ID: 17343558
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder.
    Golubchik P, Shalev L, Tsamir D, Manor I, Weizman A.
    Int Clin Psychopharmacol; 2019 May 30; 34(3):138-142. PubMed ID: 30640748
    [Abstract] [Full Text] [Related]

  • 10. Short-term efficacy and tolerability of methylphenidate in children with traumatic brain injury and attention problems.
    Ekinci O, Direk MÇ, Gunes S, Teke H, Ekinci N, Yıldırım F, Okuyaz Ç.
    Brain Dev; 2017 Apr 30; 39(4):327-336. PubMed ID: 27903419
    [Abstract] [Full Text] [Related]

  • 11. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial.
    Efron D, Jarman F, Barker M.
    Pediatrics; 1997 Dec 30; 100(6):E6. PubMed ID: 9382907
    [Abstract] [Full Text] [Related]

  • 12. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M, Hechtman L, Turgay A, Jain U, Quinn D, Ahmed TS, Yates T, Reiz JL, Donnelly GA, Harsanyi Z, Darke AC.
    J Child Adolesc Psychopharmacol; 2007 Oct 30; 17(5):675-88. PubMed ID: 17979587
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Analysis of methylphenidate's efficacy using the abbreviated version Conners' questionnaire in attention deficit hyperactivity disorder].
    de Andrade ER, Scheuer C.
    Arq Neuropsiquiatr; 2004 Mar 30; 62(1):81-5. PubMed ID: 15122438
    [Abstract] [Full Text] [Related]

  • 16. An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder.
    Zheng Y, Liang JM, Gao HY, Yang ZW, Jia FJ, Liang YZ, Fang F, Li R, Xie SN, Zhuo JM.
    Chin Med J (Engl); 2015 Nov 20; 128(22):2988-97. PubMed ID: 26608976
    [Abstract] [Full Text] [Related]

  • 17. A 6-month, open-label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention-deficit/hyperactivity disorder.
    Findling RL, Katic A, Rubin R, Moon E, Civil R, Li Y.
    J Child Adolesc Psychopharmacol; 2010 Oct 20; 20(5):365-75. PubMed ID: 20973707
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome.
    Gothelf D, Presburger G, Zohar AH, Burg M, Nahmani A, Frydman M, Shohat M, Inbar D, Aviram-Goldring A, Yeshaya J, Steinberg T, Finkelstein Y, Frisch A, Weizman A, Apter A.
    Am J Med Genet B Neuropsychiatr Genet; 2004 Apr 01; 126B(1):99-105. PubMed ID: 15048657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.